Farhad Ravandi-Kashani
Overview
Explore the profile of Farhad Ravandi-Kashani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
911
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wei Q, Hu S, Loghavi S, Toruner G, Ravandi-Kashani F, Tang Z, et al.
Am J Hematol
. 2025 Jan;
100(3):417-426.
PMID: 39871121
Chromoanagenesis (CAG) encompasses a spectrum of catastrophic genomic events, including chromothripsis, chromoanasynthesis, and chromoplexy. We studied CAG in 410 patients with a diagnosis of acute myeloid leukemia (AML), 292 newly...
2.
Urrutia S, Kantarjian H, Ravandi-Kashani F, Bueso-Ramos C, Kanagal-Shamanna R, Jabbour E, et al.
J Hematol Oncol
. 2024 Nov;
17(1):112.
PMID: 39548557
The outcomes of patients with acute myeloid leukemia (AML) and bone marrow fibrosis (MF) are not well defined. The study objectives were to evaluate the degrees of MF in AML,...
3.
Babakhanlou R, Ravandi-Kashani F, Hita A, Kontoyiannis D
J Hematol
. 2024 Apr;
13(1-2):1-11.
PMID: 38644983
Anorectal infections in neutropenic leukemia patients are a significant and potentially life-threatening complication. The pathogenesis of this condition is not entirely understood and believed to be multifactorial, including mucosal injury...
4.
Aminu M, Daver N, Godoy M, Shroff G, Wu C, Torre-Sada L, et al.
Front Immunol
. 2023 Oct;
14:1249511.
PMID: 37841255
Background: Immune checkpoint inhibitors (ICI) may cause pneumonitis, resulting in potentially fatal lung inflammation. However, distinguishing pneumonitis from pneumonia is time-consuming and challenging. To fill this gap, we build an...
5.
Babakhanlou R, Ravandi-Kashani F, Kontoyiannis D
J Hematol
. 2023 May;
12(2):59-65.
PMID: 37187499
Neutropenic enterocolitis (NEC) is a life-threatening condition occurring in severely neutropenic patients, following intensive chemotherapy for leukemia. Its pathogenesis is not entirely understood and believed to be multifactorial, including mucosal...
6.
Nguyen D, Kantarjian H, Short N, Qiao W, Ning J, Cuglievan B, et al.
Cancer
. 2023 Mar;
129(12):1856-1865.
PMID: 36892949
Background: Acute myeloid leukemia (AML) with rearrangement of lysine methyltransferase 2a gene (KMT2Ar) is characterized by chemotherapy resistance and high rates of relapse. However, additional causes of treatment failure or...
7.
Babakhanlou R, Ravandi-Kashani F
Expert Rev Hematol
. 2023 Mar;
16(3):171-180.
PMID: 36864772
Introduction: Acute myeloid leukemia (AML) is an aggressive disease predominantly affecting the elderly population. The elderly population represents a challenging group to treat and the prognosis is generally poor with...
8.
Babakhanlou R, Ravandi-Kashani F
Clin Lymphoma Myeloma Leuk
. 2022 Dec;
23(1):1-7.
PMID: 36456394
Acute myeloid leukemia (AML) is an aggressive disease predominantly affecting the elderly population. Although, up to 65% of patients with AML achieve a complete remission with standard induction chemotherapy, the...
9.
Boddu P, Senapati J, Ravandi-Kashani F, Jabbour E, Jain N, Ayres M, et al.
Cancer
. 2022 Nov;
129(4):580-589.
PMID: 36448227
Background: Nelarabine is a purine nucleoside analogue prodrug approved for the treatment of relapsed and refractory T-cell acute lymphoblastic leukemia (R/R T-ALL) and lymphoblastic lymphoma (T-LBL). Although effective in R/R...
10.
Sheshadri A, Goizueta A, Shannon V, London D, Garcia-Manero G, Kantarjian H, et al.
Cancer
. 2022 Apr;
128(14):2736-2745.
PMID: 35452134
Background: Immune checkpoint inhibitors (ICI), combined with hypomethylating agents, can be used to treat acute myeloid leukemia (AML), but this strategy results in a high rate of pneumonitis. The authors...